The estimated Net Worth of Carl Spana is at least $10.8 Million dollars as of 1 August 2019. Carl Spana owns over 50,000 units of Palatin Technologies stock worth over $8,571,208 and over the last 22 years he sold PTN stock worth over $0. In addition, he makes $2,274,410 as President, Chief Executive Officer und Director at Palatin Technologies.
Carl has made over 23 trades of the Palatin Technologies stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of PTN stock worth $43,000 on 1 August 2019.
The largest trade he's ever made was exercising 375,000 units of Palatin Technologies stock on 26 March 2010 worth over $536,250. On average, Carl trades about 31,492 units every 94 days since 2002. As of 1 August 2019 he still owns at least 5,993,852 units of Palatin Technologies stock.
You can see the complete history of Carl Spana stock trades at the bottom of the page.
Dr. Carl Spana Ph.D. serves as President, Chief Executive Officer, Director of the Company. He is co-founder of Palatin, has been our Chief Executive Officer and President since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of our wholly-owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly-held pharmaceutical company, where he was involved in scientific research in the field of immunology. He was previously a member of the board of the life science company AVAX Technologies, Inc. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.
As the President, Chief Executive Officer und Director of Palatin Technologies, the total compensation of Carl Spana at Palatin Technologies is $2,274,410. There are no executives at Palatin Technologies getting paid more.
Carl Spana is 57, he's been the President, Chief Executive Officer und Director of Palatin Technologies since 2000. There are 11 older and no younger executives at Palatin Technologies. The oldest executive at Palatin Technologies Inc. is Robert deVeer, 74, who is the Independent Director.
Carl's mailing address filed with the SEC is PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512.
Over the last 22 years, insiders at Palatin Technologies have traded over $3,929,269 worth of Palatin Technologies stock and bought 390,692 units worth $374,235 . The most active insiders traders include Austin W & Greenhouse David..., Partners L P/Ilbiotechnolog... und Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of $128,497. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth $8,298.
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
Palatin Technologies executives and other stock owners filed with the SEC include: